Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy

Clin Invest Med. 1988 Oct;11(5):377-9.

Abstract

The efficacy of intramuscular methylprednisolone acetate in maintaining the antinauseant effect of intravenous methylprednisolone sodium succinate was assessed in a prospectively-randomized, double-blind, crossover-design trial. Of 150 patients entered, 127 were evaluable. There was no statistically significant difference between methylprednisolone acetate and saline placebo, although patient preferences slightly favoured the methylprednisolone acetate for nausea, vomiting, and overall effectiveness.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Therapy, Combination
  • Humans
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / analogs & derivatives*
  • Methylprednisolone / therapeutic use
  • Methylprednisolone Acetate
  • Methylprednisolone Hemisuccinate / administration & dosage
  • Methylprednisolone Hemisuccinate / therapeutic use*
  • Nausea / chemically induced
  • Nausea / drug therapy*
  • Random Allocation
  • Vomiting / drug therapy

Substances

  • Antineoplastic Agents
  • Methylprednisolone Acetate
  • Methylprednisolone Hemisuccinate
  • Methylprednisolone